Stocktoria
Sunshine Biopharma Inc. SBFM
Sunshine Biopharma Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 | $71,410 | $21,121 | $0 | $0 | — |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110,596 | $45,563 | $10,071 | $0 | $0 | — |
| R&D expense | $604,308 | $933,902 | $1.9M | $811,858 | $672,209 | $1,728 | $15,204 | $12,800 | $0 | $32,793 |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M | -$576,874 | -$641,636 | -$1.2M | -$857,190 | -$993,108 |
| Interest expense | — | — | $137,308 | $39,412 | $328,818 | $168,105 | $115,901 | $143,463 | $104,829 | $34,732 |
| Income tax | $21,609 | -$234,858 | $395,166 | $233,304 | $0 | $0 | — | — | — | — |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | -$12.4M | -$2.8M | -$1.7M | -$2.2M | -$1.0M | -$3.5M |
| EPS (diluted) | — | $-7.32 | $-351.36 | $-1.76 | $-4.76 | — | — | — | — | — |
| Operating cash flow | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M | -$657,299 | -$495,798 | -$512,806 | -$543,520 | -$314,182 |
| Free cash flow | -$5.5M | -$14.2M | -$8.9M | -$5.4M | -$1.8M | -$658,490 | -$496,658 | -$531,656 | -$547,238 | -$317,621 |
| Cash & equivalents | — | — | — | $21.8M | $2.0M | $989,888 | $40,501 | $110,534 | $107,532 | $57,453 |
| Inventory | $13.5M | $11.3M | $5.7M | $3.3M | $105,650 | $23,771 | $15,910 | $0 | — | — |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M | $1.0M | $98,142 | $1.1M | $257,485 | $64,404 |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M | $2.0M | $833,527 | $1.2M | $830,848 | $274,104 |
| Shareholders' equity | $23.0M | $23.5M | $21.2M | $21.6M | $211,662 | -$954,837 | -$735,385 | -$55,753 | -$573,363 | -$209,700 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +4.1% | +44.7% | +454.4% | +1802.4% | +219.9% | +238.1% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.